HEALEY ALS Platform Trial
Latest Information Update: 29 May 2025
At a glance
- Drugs Censavudine (Primary) ; CNM Au8 (Primary) ; DNL 343 (Primary) ; Fosigotifator (Primary) ; Pridopidine (Primary) ; Trehalose (Primary) ; Verdiperstat (Primary) ; Zilucoplan (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms HEALEY ALS
Most Recent Events
- 28 May 2025 According to a Transposon Therapeutics media release, the TPN-101 has been selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial. Initiation of the TPN-101 regimen in the HEALEY ALS Platform Trial is expected in Q4 2025
- 06 Jan 2025 According to a Calico media release, more regimens will become available soon, with the goal of adding approximately three regimens per year.
- 10 Dec 2024 According to a Clene media release, Clene will meet with the FDA in early 2025 to review and finalize its statistical analysis plan for the EAP NfL biomarker analyses.Survival Pharmacometric Modeling: Provide analyses of NfL and related disease-specific biomarkers linked to clinical survival benefit and clinical changes from the Phase 2 trial data